Previous 10 | Next 10 |
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting- -Met Primary...
LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resul...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
Gainers: Red Cat (OTCQB:RCAT) +46%. AerSale (NASDAQ:ASLEW) +38%. Keros (NASDAQ:KROS) +28%. Camber Energy (NYSE:CEI) +27%. Puhui Wealth Investment Management (NASDAQ:PHCF) +27%. ENGlobal (NASDAQ:ENG) +25%. Paltalk (NASDAQ:PALT) +25%. Aemetis (NASDAQ:AMTX) +20%. Southwestern (NYSE:SWN) +19%. Ne...
Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...
On May 13, 2020, "Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002". On Sept 24, 2021, "Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients w...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...
ZIVO Bioscience (NASDAQ:ZIVO) +81%. Meredith Corporation (NYSE:MDP) +16% on report IAC is in purchase talks Capricor Therapeutics (NASDAQ:CAPR) +26% on positive CAP-1002 data from mid-stage duchenne muscular dystrophy study vTv Therapeutics (NASDAQ:VTVT) +21% on ascending dose study...
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction (p=0.002)– – One-Yea...
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - - The Cell & Gene Meeting on the Mesa Annual Conference: October 13 - LOS ANGELES, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or ...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...